- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03422198
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (SAVE)
Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.
After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate the non-inferiority of participant health related quality of life (HRQOL) using the Global Health Score from the Quality of Life Questionnaire Core 30 (QLQ-C30) in the 2 arms one month after treatment.
SECONDARY OBJECTIVES:
I. Compare treatment-related symptoms on HRQOL using European Organization for Research and Treatment of Cancer Endometrial Cancer Module (EORTC EN24), question 48 between the two treatment arms.
II. Compare cost effectiveness between the two treatment arms.
TERTIARY OBJECTIVES:
I. Report vaginal, bowel, and bladder symptoms on HRQOL using the EORTC EN24 the two treatment arms.
II. Evaluate toxicities between the two treatment arms. III. Compare local recurrence and document patterns of recurrence between the two treatment arms. There will be two analyses: A single interim evaluation of patterns of recurrence will be performed after a minimum of 75 participants have been accrued, and the second evaluation will be performed at the end of the study.
IV. Evaluate and compare doses to organs at risk (bladder, rectum, sigmoid colon, and urethra) and the prescribed target in the two arms.
V. Compare total distance traveled to the cancer center for study related visits.
OUTLINE: Participants are randomized to 1 of 2 arms.
Arm I: Participants undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
Arm II: Participants undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
After completion of study treatment, participants are followed up at 1, 6, and 12 months.
COHORT 2 (PILOT EXPANSION)
PRIMARY OBJECTIVES:
I. The primary objective is to evaluate the frequency and severity of participant-reported financial toxicity in participants with early-stage endometrial cancer treated with vaginal cuff-brachytherapy (VCB) at one-month post-VCB.
SECONDARY OBJECTIVES:
I. Secondary objectives include evaluation of participant-reported diet and physical activity levels and quality of life in participants with early-stage endometrial cancer treated with vaginal cuff-brachytherapy (VCB) at one-month post-VCB.
EXPLORATORY OBJECTIVES:
I. Exploratory objectives will include evaluation of differences in participant-reported financial toxicity, dietary and physical activity habits between cohorts, to assess any impact of treatment duration on outcomes.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Emma Kerr
- Phone Number: 801-587-9834
- Email: Emma.Kerr@hci.utah.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Completed
- Stanford Cancer Center
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Completed
- Loyola University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Completed
- MD Anderson
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute/University of Utah
-
Contact:
- Rachel Kingsford
- Phone Number: 801-585-0115
- Email: rachel.kingsford@hci.utah.edu
-
Principal Investigator:
- Cristina DeCesaris, MD
-
Salt Lake City, Utah, United States, 84143
- Completed
- Intermountain Medical Center / LDS Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I, with one of the following combinations of stage and grade:
- Stage IA, grade 2, 3
- Stage IB, grades 1-3
- Stage II, grades 1-3
- Participants post hysterectomy and free from residual disease
- World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2
- Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines
- Life expectancy of >2 years.
Exclusion Criteria:
- Stages of endometrial carcinoma other than described
- Previous pelvic radiotherapy
- Interval between the hysterectomy and planned start of radiotherapy exceeding 16 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Short course vaginal cuff brachytherapy
Participants undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
|
Undergo short course vaginal cuff brachytherapy
Other Names:
|
Active Comparator: Vaginal cuff brachytherapy
Participants undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
|
Undergo standard of care vaginal cuff brachytherapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life From Baseline to 1 Month
Time Frame: At 1 month post treatment
|
The European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-30 (QLQ-30) is used to evaluate quality of life in cancer patients.
The questionnaire was given before and one month following treatment.
The quality of life score ranges from 0-100, with higher scores indicating better quality of life.
Baseline scores can be found in the Baseline Characteristics module.
This outcome reports the average change from baseline to Month 1.
|
At 1 month post treatment
|
Cohort 2: Participant-Reported Financial Toxicity
Time Frame: One month after brachytherapy
|
One month post-brachytherapy, participants will be given the Functional Assessment of Chronic Illness Therapy (FACIT) - COmprehensive Score for financial Toxicity (COST) (FACIT-COST) questionnaire.
The score range is 0-44, with higher scores indicating better financial well-being.
Mean scores will be reported.
|
One month after brachytherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
USD Amount Charged for Procedures
Time Frame: Approximately 6 months after treatment
|
The amount charged to participants or their insurance in US Dollars (USD) was collected to evaluate cost of experimental versus standard of care courses of treatment.
Data was collected at approximately six months after treatment.
|
Approximately 6 months after treatment
|
Treatment-related Symptoms on HRQOL Using European Organization for Research and Treatment of Cancer Endometrial Cancer Module (EORTC EN24), Question 48
Time Frame: one month post-treatment
|
The European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Endometrial-24 (QLQ-EN24) was used to evaluate quality of life in cancer patients with endometrial cancers.
The questionnaire was given before and one month following treatment.
From this assessment, one question was selected as an indicator for this outcome, which measured whether participants felt less feminine as a result of their disease or treatment.
The score ranges from 0-100, with higher scores indicating feeling less feminine.
Baseline scores can be found in the Baseline Characteristics module.
This outcome reports the average change from baseline to Month 1.
|
one month post-treatment
|
Cohort 2: Participant-Reported Diet
Time Frame: One month after brachytherapy
|
Participants will be asked to complete the National Cancer Institute (NCI) Diet History Questionnaire 3 (DHQIII) through the NCI website.
Additional information about the questionnaire, methods, and measurements will be updated when results are reported for this outcome.
|
One month after brachytherapy
|
Cohort 2: Participant-Reported Activity Levels
Time Frame: One month after brachytherapy
|
Participants will be asked to complete the NCI Activities Completed over Time in 24-hours (ACT24) questionnaire through the NCI website.
Additional information about the questionnaire, methods, and measurements will be updated when results are reported for this outcome.
|
One month after brachytherapy
|
Cohort 2: Financial Toxicity Correlated With Quality of Life
Time Frame: One month after brachytherapy
|
Mean scores from the FACIT-COST (from Outcome Measure 2: Participant-Reported Financial Toxicity) will be correlated with mean QoL scores (from Outcome Measure 1).
Additional information about the methods and measurements will be updated when results are reported for this outcome.
|
One month after brachytherapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cristina DeCesaris, MD, Huntsman Cancer Institute/ University of Utah
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Neoplasms, Complex and Mixed
- Sarcoma
- Cystadenocarcinoma
- Neoplasms, Cystic, Mucinous, and Serous
- Ovarian Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Adenocarcinoma
- Endometrial Neoplasms
- Carcinosarcoma
- Cystadenocarcinoma, Serous
- Carcinoma, Endometrioid
- Adenocarcinoma, Clear Cell
Other Study ID Numbers
- HCI103841
- NCI-2018-00011 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage I Uterine Corpus Cancer
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingStage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial AdenocarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedLymphedema | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Stage III Vulvar Cancer | Stage IVB Vulvar Cancer | Stage 0 Cervical Cancer | Stage 0 Vulvar Cancer | Stage I Vulvar Cancer | Stage IA Cervical Cancer | Stage IB Cervical... and other conditionsUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedStage II Uterine Corpus Cancer | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingStage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Serous AdenocarcinomaUnited States
-
Stanford UniversityCompletedStage I Uterine Corpus Cancer AJCC v7 | Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Cancer Survivor | Endometrial Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7United States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedStage II Uterine Corpus Cancer | Endometrial Adenocarcinoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus CancerUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedRecurrent Uterine Corpus Carcinoma | Endometrial Carcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus Cancer | Stage IIIC1 Uterine Corpus Cancer | Stage IIIC2 Uterine Corpus CancerUnited States
Clinical Trials on Short course vaginal cuff brachytherapy
-
Xoft, Inc.CompletedEndometrial CancerUnited States
-
University of OklahomaCompletedEndometrial Cancer | Papillary Serous | Clear Cell Endometrial CancerUnited States
-
Tata Memorial CentreNot yet recruitingRectal Neoplasms
-
Walter Reed National Military Medical CenterUnknown
-
Bridgeport HospitalCompleted
-
Canadian Cancer Trials GroupCanadian Cancer Clinical Trials NetworkRecruitingEndometrial CancerCanada, Australia, Netherlands
-
Cairo UniversityUnknown
-
Karolinska InstitutetThe Swedish Research Council; Swedish Cancer SocietyCompleted
-
International Atomic Energy AgencyCompletedEsophageal CancerChina, Canada, Croatia, India, Pakistan, South Africa, Thailand
-
Kara Romano, MDRecruiting